Compile Data Set for Download or QSAR
Report error Found 26 Enz. Inhib. hit(s) with all data for entry = 9009
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135819(US8853226, 103 | US9393245, 103 | US10085990, Exam...)
Affinity DataIC50: 17nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135824(US8853226, 127 | US9393245, 127 | US10085990, Exam...)
Affinity DataIC50: 25nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135822(US8853226, 121 | US9393245, 121 | US10085990, Exam...)
Affinity DataIC50: 26nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135823(US8853226, 122 | US9393245, 122 | US10085990, Exam...)
Affinity DataIC50: 39nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135820(US8853226, 115 | US9393245, 115 | US10085990, Exam...)
Affinity DataIC50: 49nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135819(US8853226, 103 | US9393245, 103 | US10085990, Exam...)
Affinity DataIC50: 55nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135822(US8853226, 121 | US9393245, 121 | US10085990, Exam...)
Affinity DataIC50: 59nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135818(US8853226, 92 | US9393245, 92 | US10085990, Exampl...)
Affinity DataIC50: 68nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135824(US8853226, 127 | US9393245, 127 | US10085990, Exam...)
Affinity DataIC50: 73nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135816(US8853226, 54 | US9393245, 54 | US10085990, Exampl...)
Affinity DataIC50: 78nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135823(US8853226, 122 | US9393245, 122 | US10085990, Exam...)
Affinity DataIC50: 80nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135821(US8853226, 118 | US9393245, 118 | US10085990, Exam...)
Affinity DataIC50: 80nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135815(US8853226, 51 | US9393245, 51 | US10085990, Exampl...)
Affinity DataIC50: 126nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135818(US8853226, 92 | US9393245, 92 | US10085990, Exampl...)
Affinity DataIC50: 151nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135820(US8853226, 115 | US9393245, 115 | US10085990, Exam...)
Affinity DataIC50: 163nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135821(US8853226, 118 | US9393245, 118 | US10085990, Exam...)
Affinity DataIC50: 206nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135816(US8853226, 54 | US9393245, 54 | US10085990, Exampl...)
Affinity DataIC50: 338nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135817(US8853226, 84 | US9393245, 84 | US10085990, Exampl...)
Affinity DataIC50: 513nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135815(US8853226, 51 | US9393245, 51 | US10085990, Exampl...)
Affinity DataIC50: 616nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135817(US8853226, 84 | US9393245, 84 | US10085990, Exampl...)
Affinity DataIC50: 827nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135814(US8853226, 33 | US9393245, 33 | US10085990, Exampl...)
Affinity DataIC50: 1.24E+4nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135812(US8853226, 30 | US9393245, 30 | US10085990, Exampl...)
Affinity DataIC50: 1.70E+4nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135814(US8853226, 33 | US9393245, 33 | US10085990, Exampl...)
Affinity DataIC50: 2.50E+4nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135812(US8853226, 30 | US9393245, 30 | US10085990, Exampl...)
Affinity DataIC50: 2.50E+4nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135813(US8853226, 32 | US9393245, 32 | US10085990, Exampl...)
Affinity DataIC50: 2.50E+4nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135813(US8853226, 32 | US9393245, 32 | US10085990, Exampl...)
Affinity DataIC50: 2.50E+4nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
US Patent